Accelerated Left Prefrontal Transcranial Magnetic Stimulation for Functional Seizures
Open-Label Study on Feasibility, Tolerability, and Early Effects
Led by Medical University of South Carolina · Updated on 2026-09-28
30
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility, tolerability, and preliminary effects of an accelerated intermittent theta burst stimulation a-iTBS-rTMS protocol targeting the left dorsolateral prefrontal cortex for people with Psychogenic Non-Epileptic Seizures PNES or Seizure-Type Functional Neurologic Disorder FND-seiz. This open-label study aims to offer a brain-based treatment that could be more acceptable and feasible than current psychological therapies, addressing the challenges and stigma associated with FND-seiz. The investigation also includes safety monitoring and expert input to ensure proper diagnosis and management during treatment.
Participants will receive 6 to 10 TMS sessions per day, with each session delivering 600 pulses, totaling 6000 pulses daily over 3 to 5 treatment days. The goal is to complete 30 sessions 18,000 pulses targeting the left dorsolateral prefrontal cortex at a specific brain location called Beam F3. This accelerated treatment schedule is designed to mimic clinical practice and improve treatment feasibility for patients with FND-seiz. The protocol uses a MagVenture MagPro TMS device and includes a safety protocol developed with epilepsy and brain stimulation experts.
During the study, participants will be assessed before treatment, throughout the 3 to 5-day treatment period, and at a 4-week follow-up visit. Researchers will monitor the number of treatment sessions completed, delivery patterns of TMS pulses, and any adverse events. They will also evaluate seizure frequency, stigma, quality of life, depression, PTSD, somatic symptoms, psychosocial functioning, psychological distress, and clinical impressions of improvement. These assessments aim to understand how TMS may affect both FND-seiz symptoms and related psychological conditions.
CONDITIONS
Brief Title
Accelerated TMS for Seizure-Type Functional Neurologic Disorders
Research Team
R
Recruitment Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Accelerated theta‑burst TMS
Guideline‑recommended psychological therapy
What it is
An experimental accelerated theta‑burst transcranial magnetic stimulation (TMS) protocol delivering multiple sessions per day over several days to the left dorsolateral prefrontal cortex.
A psychological treatment approach such as functional seizure‑specific cognitive behavioral therapy currently recommended in clinical guidelines for functional seizures.
Role in trial
Study intervention delivered to all enrolled participants (single‑arm design).
Not evaluated within this trial; serves as current treatment alternative outside the study.
Primary use
To explore feasibility, delivery patterns, completion, and safety of accelerated TMS in functional seizures.
To reduce seizure frequency, improve quality of life and psychosocial functioning in functional seizures.
How it is given or performed
Delivered over 3 to 5 days with multiple 600‑pulse theta‑burst sessions per day using a MagVenture MagPro TMS system targeted to l‑dlPFC.
Psychological therapy typically involves scheduled therapy sessions over weeks delivered by trained clinicians.
Evidence status
Evidence limited to this early‑phase study; efficacy yet to be established.
Supported by multiple Class II‑III studies and guideline recommendation showing possible reductions in seizure frequency and improved quality of life.
Important risks
Unknown; safety being assessed in this study through adverse and serious adverse event monitoring.
Generally well tolerated with low reported risk in guideline documentation.
Important limitations
Small sample, single‑group early‑phase design without comparator limits conclusions on efficacy and generalizability.
Existing evidence is qualified as possibly effective; long‑term outcomes and optimal formats are not fully established.
Patient impact
Not yet known; outcomes such as seizure reduction and remission are being measured but results are unavailable.
Possible improvements in seizure control, anxiety, quality of life, and functioning based on multiple studies.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 65Years
All Genders
Eligibility Criteria
You may qualify if you...
Between 18 and 65 years old
English speaking, able to read, write, and provide informed consent
Diagnosis of Functional Seizures confirmed by a neurologist or epileptologist following ILAE guidelines
Prior normal 24-hour video EEG without epileptiform activity
Symptoms lasting more than 3 months with monthly non-epileptic seizures
Not currently in psychotherapy and agree to avoid it during the study
May continue current psychotropic medications without changes during the trial
In good general health
Females aged 18 to 50 must have a negative urine pregnancy test within 72 hours before first treatment
You will not qualify if you...
History or suspicion of epileptic seizures or epilepsy
Ongoing psychosis, mania, or active alcohol or substance use disorder
Positive drug test for cocaine, amphetamines, barbiturates, or opiates within the past year
Active suicidal intent or high depression score on screening
Use of medications that may increase seizure risk with TMS at risky doses
History of brain surgery or relevant structural brain lesions
Significant or unstable cardiac, metabolic, oncologic, psychiatric, developmental, or neurologic conditions
Participation in another clinical trial within the past month
Previous exposure to TMS
Contraindications to TMS such as implants or seizure risk factors
Current pregnancy or planning pregnancy without contraception
Prisoner or in police custody at screening
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 3 to 5 days
Participants receive accelerated intermittent theta burst TMS sessions targeting the left dorsolateral prefrontal cortex over 3 to 5 days, aiming for 30 total sessions.
Multiple sessions per day with 15-minute breaks between
Follow-up
Duration - 4 weeks
Participants are monitored through assessments and questionnaires to evaluate seizure frequency, symptoms, and treatment effects at 4 weeks after treatment.
1 follow-up visit
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Feasibility Study Comparing Two Therapies for Functional Seizures in Children and Teens Aged 11 to 18
Accelerated Left Prefrontal Transcranial Magnetic Stimulation for Functional Seizures
Open-Label Study on Feasibility, Tolerability, and Early Effects
Sluggish Cognitive Tempo Symptoms in Adults with Functional Neurological Symptom Disorder Compared to Healthy Controls A Cross-Sectional Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force.